Recombinant Dog 3-hydroxyacyl-CoA dehydratase 1 (PTPLA)

What is the relationship between HACD1 and PTPLA?

3-hydroxyacyl-CoA dehydratase 1 (HACD1) and protein tyrosine phosphatase-like A (PTPLA) are the same gene product. Initially annotated as PTPLA based on sequence homology, functional studies revealed its actual enzymatic role in fatty acid elongation as a dehydratase. The gene is commonly referenced as HACD1 in recent literature focusing on biochemical function, while PTPLA nomenclature persists in genetic studies, particularly those involving canine myopathies. Researchers should be aware of both designations when conducting literature searches to ensure comprehensive review of available data .

What is the functional role of HACD1/PTPLA in cellular metabolism?

HACD1 catalyzes the dehydration of 3-hydroxyacyl-CoA to 2,3-trans-enoyl-CoA during very long chain fatty acid (VLCFA) elongation. Enzymatic assays demonstrate that the full-length HACD1 protein catalyzes the dehydration of 3-hydroxypalmitoyl-CoA into 2,3-trans-hexadecenoyl-CoA in a dose-dependent manner. This activity is not exhibited by truncated isoforms (HACD1-D5, HACD1-167) or mutants with alterations to essential residues like Y171A . This catalytic step is critical for maintaining proper membrane composition and fluidity, with particular importance in muscle tissue development and function .

What mutations in canine HACD1/PTPLA are associated with myopathies?

The primary pathogenic mutation identified in Labrador retrievers with centronuclear myopathy (CNM) is a SINE (short interspersed nuclear element) insertion within exon 2 of the PTPLA gene. This mutation creates complex splicing defects in skeletal muscles, resulting in approximately 99% reduction in wild-type PTPLA transcripts, effectively creating a loss-of-function scenario . Molecular characterization through amplification and sequencing of the affected region shows remarkable conservation of this mutation across affected dogs worldwide, with no length polymorphisms or sequence variations detected in the inserted SINE .

What methods are most effective for genotyping the HACD1/PTPLA mutation in canine populations?

PCR-based genotyping targeting the SINE insertion site has proven highly effective for large-scale population screening. This approach was successfully employed to genotype 7,426 Labradors from 18 countries, identifying carriers in 13 countries. DNA extraction from blood samples or cheek swabs followed by PCR amplification with primers flanking the insertion site will yield different fragment sizes for wild-type and mutant alleles. Gel electrophoresis can then clearly distinguish between homozygous wild-type, heterozygous carrier, and homozygous affected genotypes. For confirmation, sequencing of PCR products can verify the exact nature of the mutation .

How can researchers assess HACD1 enzymatic activity in experimental settings?

Two complementary approaches are recommended for evaluating HACD1 enzymatic function:

• In vitro enzymatic assays: Using purified recombinant HACD1 protein, researchers can measure the dehydration of 3-hydroxypalmitoyl-CoA to 2,3-trans-hexadecenoyl-CoA. This activity can be quantified using HPLC or LC-MS/MS to track substrate depletion and product formation. Control experiments should include known inactive variants (such as HACD1-Y171A) and dose-dependency studies to establish enzyme kinetics .

• Yeast complementation studies: Expression of functional HACD1 in PHS1-shutdown yeast strains (PHS1 being the yeast ortholog) can rescue growth defects, providing a functional readout in a cellular context. This approach has confirmed that full-length HACD1, but not truncated isoforms or inactive mutants, complements PHS1 deficiency .

Both methods provide valuable insights, with the in vitro approach offering quantitative biochemical data and the yeast system providing assessment of function in a cellular environment.

What are the substrate specificities of different HACD family members?

Comparative analysis of HACD family members reveals overlapping but distinct substrate preferences:

This functional redundancy explains why HACD1 knockout models retain substantial 3-hydroxyacyl-CoA dehydratase activity, as HACD2 can partially compensate for HACD1 deficiency. Researchers investigating substrate specificity should employ fatty acid elongation assays using various acyl-CoA/fatty acid substrates rather than direct measurement with 3-OH acyl-CoA substrates .

What critical residues and domains are essential for HACD1 function?

Structure-function studies have identified key elements required for HACD1 enzymatic activity:

• Tyrosine 171 (Y171): Point mutation of this residue to alanine (Y171A) completely abolishes enzymatic activity and the ability to rescue PHS1-deficient yeast, indicating its critical role in catalysis .

• Full-length protein structure: Truncated isoforms (HACD1-D5, HACD1-167) lack dehydratase activity, highlighting the importance of complete protein architecture .

• Fifth transmembrane segment: Contains the catalytically essential residues, including Y171 and a conserved glutamate. This region is encoded by exon 6 in mice, and targeted disruption of this exon creates functional knockout models .

For researchers conducting mutagenesis studies, these regions should be prioritized when investigating structure-function relationships or designing dominant-negative constructs.

How do canine and murine HACD1 deficiency models compare?

Both species demonstrate similar yet distinct phenotypic manifestations of HACD1 deficiency:

This phenotypic difference may reflect species-specific compensation mechanisms or differential tissue expression patterns of other HACD family members. Notably, no compensatory increases in HACD2, HACD3, or HACD4 mRNA levels were observed in Hacd1 knockout skeletal muscle, suggesting that baseline expression of these enzymes is sufficient for partial functional compensation .

What explains the variable phenotypic expression in dogs with identical HACD1/PTPLA mutations?

Affected Labradors homozygous for the PTPLA mutation exhibit a spectrum of clinical severity that cannot be explained by variations in the mutant allele itself. Detailed analysis revealed:

• SINE sequence conservation: Visual comparison and sequencing of the PTPLA CNM allele from affected dogs showed no fragment length polymorphisms or base pair variations within the inserted SINE sequence .

• Potential mechanisms: The variable expressivity likely depends on unidentified modifiers such as:

  • Functional polymorphisms elsewhere in the PTPLA gene

  • Variations in functionally redundant paralogs (particularly HACD2)

  • Additional genetic modifiers that influence the fatty acid elongation pathway

  • Environmental or epigenetic factors affecting gene expression

Researchers investigating this variability should consider whole-genome sequencing approaches, expression profiling of all HACD family members in affected tissues, and case-control studies examining potential environmental influences on phenotype severity.

What cellular processes are disrupted by HACD1 deficiency leading to myopathy?

The pathophysiological mechanisms linking HACD1 deficiency to muscle disease involve several interconnected pathways:

• Membrane composition alterations: Impaired very long chain fatty acid elongation affects cellular membrane composition and fluidity, which is particularly critical in developing muscle fibers .

• Muscle fiber formation: Studies indicate that HACD1 regulates membrane composition and fluidity in ways that promote proper muscle fiber formation. Deficiency leads to structural abnormalities that manifest as congenital myopathy .

• Nuclear positioning: The progressive nuclear centralization observed in affected dogs represents a hallmark of centronuclear myopathies, suggesting disruption of mechanisms controlling nuclear localization within muscle fibers .

These processes reflect the importance of proper membrane composition in multiple aspects of muscle development and function. Research approaches should include lipidomic analysis of membrane composition, electron microscopy to assess ultrastructural changes, and investigation of nuclear positioning machinery in affected muscle fibers.

What therapeutic strategies show promise for HACD1/PTPLA-associated myopathies?

Several potential intervention approaches warrant investigation:

• Gene replacement therapy: Viral vector-mediated delivery of functional HACD1/PTPLA specifically to muscle tissue could address the fundamental genetic deficiency. Adeno-associated virus (AAV) vectors with muscle-specific promoters would be most appropriate for this approach.

• HACD2 upregulation: Given the functional redundancy between HACD1 and HACD2, pharmacological or genetic approaches to enhance HACD2 expression might compensate for HACD1 deficiency. High-throughput screening for compounds that selectively upregulate HACD2 in muscle tissue could identify candidate therapeutics.

• Dietary supplementation: Strategic supplementation with specific very long chain fatty acids might bypass the elongation defect. Controlled feeding studies in canine models would help establish efficacy and optimal formulations.

• Read-through therapies: For mutations creating premature stop codons in HACD1 (though not the primary canine SINE insertion), compounds promoting translational read-through could enable production of full-length protein.

The canine model provides an excellent large animal system for testing these approaches, offering advantages in terms of size, lifespan, and physiological relevance to human disease .

How can the canine HACD1/PTPLA model contribute to broader understanding of centronuclear myopathies?

Centronuclear myopathies in humans result from mutations in approximately 70 different genes, including members of the myotubularin, dynamin, and amphiphysin families. The HACD1-deficient Labrador model offers unique research opportunities:

• Integrative pathway analysis: Comparing molecular pathways disrupted in different genetic forms of CNM could reveal convergent mechanisms and potential therapeutic targets. Research approaches should include comparative transcriptomics and proteomics between HACD1-deficient tissues and other CNM models.

• Large animal drug testing platform: The Labrador model permits evaluation of therapies in a system more closely resembling human physiology than rodent models, particularly for assessing drug delivery, pharmacokinetics, and long-term efficacy .

• Novel gene discovery: Approximately 30% of human CNM cases remain genetically unresolved. Comparative studies between canine and human CNM could identify novel candidate genes in the remaining unexplained cases.

The relatively high prevalence of the mutation in pet Labradors worldwide provides a unique opportunity for natural history studies and clinical trial recruitment that is unavailable for most other large animal models of genetic disease .